Filter Results
:
(213)
Show Results For
- All HBS Web (213)
- Faculty Publications (140)
Show Results For
- All HBS Web (213)
- Faculty Publications (140)
- 24 Apr 2014
- News
"Paying forward" as a mentor to high-tech and science start-ups
Emile Bellott (AM 1973, PhD 1976, MBA 1978), a consultant in bio-pharmaceuticals, talks about his work as a mentor to new companies in high tech and medicine. (Published April 2014)
View Details
- April 2018 (Revised September 2018)
- Case
Impact Investing for Cancer
By: Richard G. Hamermesh and Matthew G. Preble
It is early 2018, and Emily Park, managing director of impact for the Abreu Family Office, is meeting the next day with Tomás and Maria Abreu to discuss the various ways in which the Abreus can allocate a planned $100 million to make a meaningful difference in cancer...
View Details
Keywords:
Impact Investing;
Investment;
Health Disorders;
Philanthropy and Charitable Giving;
Decision Choices and Conditions
Hamermesh, Richard G., and Matthew G. Preble. "Impact Investing for Cancer." Harvard Business School Case 818-068, April 2018. (Revised September 2018.)
- 01 Jun 2013
- News
Lab Work
After 16 years at the Australian technology-transfer organization UniQuest, managing director David Henderson (MBA 1989) is moving on to new challenges. Looking back on the experience of shepherding technologies from the university to the marketplace—the...
View Details
- April 1991 (Revised November 1997)
- Case
Levi Strauss & Co. and the AIDS Crisis
Keywords:
Health Disorders;
Employee Relationship Management;
Corporate Social Responsibility and Impact;
Apparel and Accessories Industry
Tedlow, Richard S. "Levi Strauss & Co. and the AIDS Crisis." Harvard Business School Case 391-198, April 1991. (Revised November 1997.)
- January 2018
- Article
The Effect of Cost Sharing on an Employee Weight Loss Program: A Randomized Trial
By: Leslie K. John, Andrea Troxel, William Yancy, Joelle Y. Friedman, Jingsan Zhu, Lin Yang, Robert Galvin, Karen Miller-Kovach, Scott Halpern, George Loewenstein and Kevin Volpp
Purpose: We tested the effects of employer subsidies on employee enrollment, attendance, and weight loss in a nationally-available weight management program.
Design: A randomized trial tested the impact of employer subsidy: 100%; 80% 50% and a hybrid 50% subsidy... View Details
Design: A randomized trial tested the impact of employer subsidy: 100%; 80% 50% and a hybrid 50% subsidy... View Details
Keywords:
Affordable Care Act (ACA);
Subsidies;
Weight Loss;
Obesity;
Incentives;
Behavioral Economics;
Motivation and Incentives;
Behavior;
Health Disorders;
Health Care and Treatment;
Compensation and Benefits;
United States
John, Leslie K., Andrea Troxel, William Yancy, Joelle Y. Friedman, Jingsan Zhu, Lin Yang, Robert Galvin, Karen Miller-Kovach, Scott Halpern, George Loewenstein, and Kevin Volpp. "The Effect of Cost Sharing on an Employee Weight Loss Program: A Randomized Trial." American Journal of Health Promotion 32, no. 1 (January 2018): 170–176.
- 2009
- Working Paper
Applying the Care Delivery Value Chain: HIV/AIDS Care in Resource Poor Settings
By: Joseph Rhatigan, Sachin H Jain, Joia S. Mukherjee and Michael E. Porter
The care delivery value chain is a framework that can help conceptualize the organization and structure of care delivery for medical conditions. We apply this framework to HIV/AIDS care in resource-limited settings. Several conclusions arise than can help inform...
View Details
Keywords:
Customer Value and Value Chain;
Framework;
Health Care and Treatment;
Health Disorders;
Service Delivery
Rhatigan, Joseph, Sachin H Jain, Joia S. Mukherjee, and Michael E. Porter. "Applying the Care Delivery Value Chain: HIV/AIDS Care in Resource Poor Settings." Harvard Business School Working Paper, No. 09-093, February 2009.
- 23 Jan 2019
- News
The Promise of Personalized Medicine
Subscribe on iTunes Subscribe on SoundCloud More Skydeck episodes As a little kid, Rich Horgan (MBA 2018) doesn’t remember thinking much about the differences between himself and his younger brother, Terry. But as he started to get older, he started to ask questions:...
View Details
- February 2006 (Revised February 2009)
- Case
AIDS in Brazil
By: Rohit Deshpande and Ricardo Reisen de Pinho
Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra.
View Details
Keywords:
Price;
Government and Politics;
Health Care and Treatment;
Health Disorders;
Rights;
Negotiation;
Business and Government Relations;
Pharmaceutical Industry;
Brazil
Deshpande, Rohit, and Ricardo Reisen de Pinho. "AIDS in Brazil." Harvard Business School Case 506-062, February 2006. (Revised February 2009.)
- 24 Apr 2014
- News
Personal crises inform a life’s work
One of the youngest women to attend HBS, Amy Schiffman Langer (MBA 1977) was building a successful investment banking career when a cancer diagnosis at age 29 spurred her to volunteer at the National Alliance of Breast Cancer Organizations. She eventually became the...
View Details
- 01 Mar 2017
- News
How Deep Brain Stimulation Could Change Medicine
tremors in his bow whenever he practiced, he immediately knew that something in his body was out of sync. He was diagnosed with essential tremor, a neurological disorder that causes involuntary and rhythmic shaking of the arms or hands....
View Details
Keywords:
Janelle Nanos
- 2017
- Article
Blunted Ambiguity Aversion During Cost-Benefit Decisions in Antisocial Individuals
By: Joshua W. Buckholtz, Uma R. Karmarkar, Shengxuan Ye, Grace M. Brennan and Arielle Baskin-Sommers
Antisocial behavior is often assumed to reflect aberrant risk processing. However, many of the most significant forms of antisocial behavior, including crime, reflect the outcomes of decisions made under conditions of ambiguity rather than risk. While risk and...
View Details
Keywords:
Ambiguity;
Neuroscience;
Neuroeconomics;
Choice;
Psychology;
Decision Choice And Uncertainty;
Behavior;
Decision Choices and Conditions;
Cost vs Benefits;
Health Disorders
Buckholtz, Joshua W., Uma R. Karmarkar, Shengxuan Ye, Grace M. Brennan, and Arielle Baskin-Sommers. "Blunted Ambiguity Aversion During Cost-Benefit Decisions in Antisocial Individuals." Art. 2030. Scientific Reports 7 (2017).
- 01 Jun 2017
- News
Turning Point: Addiction’s Impact
image by Jeffrey Decoster image by Jeffrey Decoster I was blindsided when my daughter told me, “I’m a heroin addict.” It was November 16, 2009, at a meeting with her drug counselor at Boston College. After I uttered a profanity and slammed my keys on the table, Amy...
View Details
Keywords:
Melissa Weiksnar (MBA 1982)
- 08 Feb 2021
- News
How Managers Can Support Employees with Chronic Illnesses
- 04 Sep 2014
- News
Our focus was to get drug companies to invest money in ALS
He can no longer walk, talk, or swallow, but Avi Kremer (MBA 2007) won’t let that slow down his pursuit of a cure for ALS, a progressive neurodegenerative disease. As founder of Prize4Life, the nonprofit he launched in 2006 with HBS classmates and professors, Kremer...
View Details
- September 2006 (Revised July 2012)
- Case
PSI India—Will Balbir Pasha Help Fight AIDS? (A)
By: Elie Ofek and Peter Wickersham
In 2002, Population Services International (PSI) was committed to curbing the growing HIV/AIDS epidemic in India. Sanjay Chaganti, program director of HIV/AIDS at PSI India, has to decide on the best communication strategy to achieve this goal. Up to this date most...
View Details
Keywords:
Advertising Campaigns;
Communication Strategy;
Health Disorders;
Marketing Communications;
Social Marketing;
Social Enterprise;
India
Ofek, Elie, and Peter Wickersham. "PSI India—Will Balbir Pasha Help Fight AIDS? (A)." Harvard Business School Case 507-032, September 2006. (Revised July 2012.)
- 23 Mar 2016
- News
Curing Parkinson’s Disease
HBS alumni Jonathan Solomon and Hampus Hillerstrom (both MBA 2007) play an important role in Jon Palfreman’s recent book Brain Storms: The Race to Unlock the Mysteries of Parkinson’s Disease. As the cofounders of NeuroPhage Pharmaceuticals, the pair is working to...
View Details
- October 2020 (Revised November 2023)
- Case
COVID-19 Testing at Everlywell
By: Jeffrey J. Bussgang and Olivia Hull
In March 2020, as COVID-19 spreads rapidly across the U.S., Everlywell founder Julia Cheek considers how to respond as a small start-up specializing in at-home lab testing. After making dramatic budget cuts, she decides to pivot the organization to address the...
View Details
Keywords:
Entrepreneurship;
Business Strategy;
Venture Capital;
Health Care and Treatment;
Health Disorders;
Leading Change;
Technology Adoption;
Digital Platforms;
Competitive Strategy;
Science;
Adaptation;
Corporate Social Responsibility and Impact;
Crisis Management;
Social Entrepreneurship;
Ethics;
Government Legislation;
Health;
Health Testing and Trials;
Health Pandemics;
Health Industry;
Health Industry;
Health Industry;
Texas;
United States
Bussgang, Jeffrey J., and Olivia Hull. "COVID-19 Testing at Everlywell." Harvard Business School Case 821-001, October 2020. (Revised November 2023.)
- April 1989 (Revised January 1994)
- Case
Novo Industri
By: Michael E. Porter and Michael J. Enright
Describes the structure of the insulin industry, a treatment for diabetes and Novo's strategy and competitive position in early 1982. The industry is undergoing significant change and Novo must decide how to defend and build its international position. Designed as an...
View Details
Keywords:
Change;
Global Strategy;
Industry Structures;
Alliances;
Competitive Strategy;
Health Disorders;
Pharmaceutical Industry
Porter, Michael E., and Michael J. Enright. "Novo Industri." Harvard Business School Case 389-148, April 1989. (Revised January 1994.)
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater...
View Details
Keywords:
Governing Rules, Regulations, and Reforms;
Health Disorders;
Health Testing and Trials;
Power and Influence;
Competitive Strategy;
Pharmaceutical Industry;
European Union;
Germany;
United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.